BIOX NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Bioceres Crop Solutions Corp · Basic Materials · Agricultural Inputs

Open interactive chart View report data Download investor PDF
Latest close 0.34 USD
-2.0% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is -41.0% below the Trend Line and sits at 1.2% of its 52-week range. The latest completed week returned -2.0%, after a 2.5% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 51/100 conviction, while the latest news-sentiment score is 45/100. Near-term considerations: volume confirmation is below normal; earnings are due in 40d.

Setup score 17 out of 100
Latest Close 0.34 USD 24 Jul 2026
1W Return -2.0% latest completed week
4W Return 2.5% short-term follow-through
12W Return -26.7% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 0.5x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -2.0% Latest completed week; four-week move 2.5%. Indicator stack 0/36 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 40.06% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 51/100 conviction; expected move 508.7%. News sentiment 45/100 52 relevant articles in the latest sentiment read. Event risk 40d Next report is scheduled for 08 Sep 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -41.0% below the Trend Line and sits at 1.2% of its 52-week range. The latest completed week returned -2.0%, after a 2.5% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0112-week average 0.03

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure11/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.01Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 2.5% over four weeks, -26.7% over 12 weeks, and -90.9% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-2.0%
4W2.5%
12W-26.7%
26W-71.4%
52W-90.9%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.21Latest activity-pressure read.
Pressure change-130.9%Four-week change in activity pressure.
Leadership-74.40Latest relative-leadership reading.
RS change8.1%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 30 Jun 2025 Field coverage 88% Model confidence 84%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength71/100Blend of value, momentum, and quality. Underlying universe rank 30; rank 1 is best.
Value60/100Relative valuation strength. Underlying universe rank 41; rank 1 is best.
Quality58/100Profitability and accounting quality. Underlying universe rank 43; rank 1 is best.
Momentum60/100Medium-term price momentum. Underlying universe rank 41; rank 1 is best.
Growth60/100Revenue and earnings growth. Underlying universe rank 41; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
0.1x
Market value relative to trailing revenue.
EV / EBITDA
139.3x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
23.4%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
37.0%
Gross profit retained from each unit of revenue.
Operating margin
-4.8%
Operating profit retained from revenue.
Free-cash-flow margin
24.5%
Free cash flow generated from revenue.
Return on invested capital
-3.3%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-29.8%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
0.0%
Cash dividends relative to market value.
Buyback yield
4.2%
Net share repurchases relative to market value.
Shareholder yield
4.2%
Dividend yield plus net buyback yield.
Net debt / EBITDA
114.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

BIOX shows volatility options pressure with a 51/100 conviction score, put-call volume ratio of 0.13, expected move of 508.7%, and Sharemaestro trend signal inactive.

Conviction51/100
Expected move508.7%
Put/call volume0.13
Pressure89
Speculation17
Volatility96
Trend agreement0
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment45/100

Weighted news tone is neutral across 52 relevant articles.

1 positive · 40 neutral · 11 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings40dNext report is scheduled for 08 Sep 2026; event risk rises as the date approaches.
Options expected move508.7%Nearest-chain priced movement where available.
52-week drawdown-91.1%Distance below the 52-week high.
13-week volatility6.1%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher10 of 2616 weeks finished lower.
Best week+38.2%Week of 3 Apr.
Worst week-32.5%Week of 6 Feb.
Latest week-2.0%Week of 24 Jul.

Shape of recent returns

Strong gains4
Modest gains6
Flat weeks0
Modest losses5
Sharp losses11
Recent vol6.1%13-week weekly-return volatility.
Base vol11.9%52-week weekly-return volatility.
Up/down split18/34Count of positive and negative weeks in the 52-week window.
Average skew7.8% / -9.9%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape15/100

Trend, activity pressure, participation, and risk combine to a 15/100 tape read.

 Indicator analysis28/100

Latest 12-week confirmation: trend 0/12, activity pressure 11/12, relative leadership 0/12.

Activity pressure 0.01; No reversal markers Next-Week ExpectancyNegative 40.06%

Next-week expectancy is negative with a 40.06% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors62/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 14 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options35/100

BIOX shows volatility options pressure with a 51/100 conviction score, put-call volume ratio of 0.13, expected move of 508.7%, and Sharemaestro trend signal inactive.

Volatility · Volatility expansion watch · Expected move 508.7% Sentiment45/100

Weighted news tone is neutral across 52 relevant articles.

Bioceres Crop Solutions Corp (BIOX) Income Statement Insiders50/100

No recent insider transaction evidence is stored.

 Earnings40d

Next report is scheduled for 08 Sep 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20260.34 USD-2.0%0.58 USD6.46 USD-0.21-74.40544.2KOff
17 Jul 20260.35 USD2.0%0.61 USD6.54 USD0.06-75.75502.3KOff
10 Jul 20260.34 USD3.7%0.65 USD6.62 USD0.28-78.40682.3KOff
3 Jul 20260.33 USD-1.1%0.69 USD6.70 USD0.54-80.05858.9KOff
26 Jun 20260.33 USD-10.3%0.73 USD6.78 USD0.66-80.991.4MOff
19 Jun 20260.37 USD-11.2%0.77 USD6.86 USD0.69-80.911.5MOff
12 Jun 20260.42 USD-0.0%0.81 USD6.95 USD0.69-79.16732.9KOff
5 Jun 20260.42 USD-5.8%0.85 USD7.03 USD0.72-79.751.9MOff
29 May 20260.45 USD7.7%0.90 USD7.10 USD0.72-80.621.5MOff
22 May 20260.41 USD-3.5%0.95 USD7.18 USD0.65-82.441.1MOff
15 May 20260.43 USD-8.8%1.00 USD7.25 USD0.60-82.462.1MOff
8 May 20260.47 USD0.4%1.04 USD7.32 USD0.49-81.691.4MOff
1 May 20260.47 USD-13.5%1.07 USD7.39 USD0.32-81.651.2MOff
24 Apr 20260.54 USD-8.9%1.10 USD7.46 USD0.12-79.372.0MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.